Janssen debuts schizophrenia awareness doc

Share this article:
Janssen debuts schizophrenia awareness doc
Janssen debuts schizophrenia awareness doc
Johnson & Johnson is back in the film game with Janssen's half-hour documentary Living with Schizophrenia: A Call for Hope and Recovery.

The unbranded film, which follows several young people with schizophrenia and their families, aims to lessen the fear and stigma associated with the condition. It debuted Friday in Washington, DC, and will be distributed through a series of community-based events, via advocacy groups and online at hopeandrecoveryfilm.com.

The film, said director Emily Abt, “highlights the stories that don't make the headlines – the stories of hope and promise.” Abt's grandmother struggled with schizophrenia.

Janssen's Risperdal and Invega franchises are indicated for the treatment of schizophrenia, and the company sponsored an earlier documentary on the topic. In 2007, J&J's Centocor unit sponsored “Innerstate” an hour-long documentary following a similar formula, following several young people struggling with autoimmune disorders. Centocor makes Remicade for rheumatoid arthritis, psoriasis and Crohn's Disease.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...